Cancer Letters
Volume 291, Issue 2 , Pages 230-236 , 28 May 2010

Fhit loss in lung preneoplasia: Relation to DNA damage response checkpoint activation

  • Roberto Cirombella

      Affiliations

    • Division of Pathology, II University of Rome “La Sapienza”, Ospedale Santo Andrea, Rome, Italy
    • ,
  • Giuseppe Montrone

      Affiliations

    • Division of Pathology, Ospedale San Camillo Forlanini, Rome, Italy
    • ,
  • Antonella Stoppacciaro

      Affiliations

    • Division of Pathology, II University of Rome “La Sapienza”, Ospedale Santo Andrea, Rome, Italy
    • ,
  • Simona Giglio

      Affiliations

    • Division of Pathology, II University of Rome “La Sapienza”, Ospedale Santo Andrea, Rome, Italy
    • ,
  • Stefano Volinia

      Affiliations

    • Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, OH, USA
    • ,
  • Paolo Graziano

      Affiliations

    • Division of Pathology, Ospedale San Camillo Forlanini, Rome, Italy
    • ,
  • Kay Huebner

      Affiliations

    • Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, OH, USA
    • Corresponding Author InformationCorresponding authors. Addresses: Ohio State University Comprehensive Cancer Center, Biomedical Research Tower, Rm 916, 460W. 12th Ave., Columbus, OH 43210, USA. Tel.: +1 614 292 4850; fax: +1 614 688 8675 (K. Huebner). Division of Pathology, II University of Rome “La Sapienza”, Ospedale Santo Andrea, Rome, Italy (A. Vecchione).
    • ,
  • Andrea Vecchione

      Affiliations

    • Division of Pathology, II University of Rome “La Sapienza”, Ospedale Santo Andrea, Rome, Italy
    • Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, OH, USA
    • Corresponding Author InformationCorresponding authors. Addresses: Ohio State University Comprehensive Cancer Center, Biomedical Research Tower, Rm 916, 460W. 12th Ave., Columbus, OH 43210, USA. Tel.: +1 614 292 4850; fax: +1 614 688 8675 (K. Huebner). Division of Pathology, II University of Rome “La Sapienza”, Ospedale Santo Andrea, Rome, Italy (A. Vecchione).

Received 1 September 2009 ,Revised 21 October 2009 ,Accepted 22 October 2009.

References 

  1. Tsantoulis PK, Kotsinas A, Sfikakis PP, Evangelou K, Sideridou M, Levy B, et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene. 2008;27:3256–3264
  2. Thavathiru E, Ludes-Meyers JH, MacLeod MC, Aldaz CM. Expression of common chromosomal fragile site genes WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens UV and BPDE but not by IR. Mol. Carcinogen. 2005;44:174–182
  3. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, et al. The fragile genes, FHIT and WWOX, are inactivated coordinately in invasive breast carcinoma. Cancer. 2004;100:1605–1614
  4. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998;58:5032–5037
  5. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 1999;59:4798–4803
  6. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60:1949–1960
  7. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, et al. Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology. 2001;61:205–211
  8. Zhao P, Liu W, Lu YL. Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J. Gastroenterol. 2005;11:5735–5738
  9. Butler D, Collins C, Mabruk M, Leader MB, Kay EW. Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol. Oncol. 2002;86:144–149
  10. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, et al. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin. Cancer Res. 2000;6:3505–3510
  11. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–913
  12. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870
  13. Bartek J, Bartkova J, Lukas J. DNA damage signaling guards against activated oncogenes and tumour progression. Oncogene. 2007;26:7773–7779
  14. Ishii H, Mimori K, Inoue H, Inageta T, Ishikawa K, Semba S, et al. Fhit modulates the DNA damage checkpoint response. Cancer Res. 2006;66:11287–11292
  15. Pichiorri F, Ishii H, Okumura H, Trapasso F, Wang Y, Huebner K. Molecular parameters of genome instability: roles of fragile genes at common fragile sites. J. Cell. Biochem. 2008;104:1525–1533
  16. Yutori H, Semba S, Kumori T, Yokozaki H. Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells. Cancer Sci. 2008;99:524–530
  17. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 2003;278:12207–12213
  18. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, et al. Overexpression of a kinaseinactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 1998;17:159–169
  19. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000;60:5934–5936
  20. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998;282:1893–1897
  21. Helt CE, Cliby WA, Keng PC, Bambara RA, O’Reilly MA. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J. Biol. Chem. 2005;280:1186–1192
  22. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene. 2006;25:4381–4388
  23. Arlt MF, Durkin SG, Ragland RL, Glover TW. Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst). 2006;5:1126–1135(Review)
  24. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM. Molecular and genetic aspects of lung cancer. Am. J. Respir. Crit. Care Med. 2000;161:1355–1367
  25. Alberts WM. Introduction: diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132:20S–22S
  26. Patz EF, Goodman PC, Bepler G. Screening for lung cancer. New Engl. J. Med. 2000;343:1627–1633
  27. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu. Rev. Pathol. 2006;1:331–348
  28. Durkin SG, Ragland RL, Arlt MF, Mulle JG, Warren ST, Glover TW. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc. Natl. Acad. Sci. USA. 2008;105:246–251
  29. Indinnimeo M, Giarnieri E, Stazi A, Cicchini C, Brozzetti S, Valli C, et al. Early stage human colorectal cancer: prognostic value of nm23–H1 protein overexpression. Cancer Lett. 1997;111:1–5
  30. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979;6:65–70
  31. Stucki M, Jackson SP. GammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst). 2006;5:534–543
  32. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, et al. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am. J. Respir. Crit. Care Med. 2009;179:396–401
  33. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 2008;8:363–369(Review)

PII: S0304-3835(09)00650-8

doi: 10.1016/j.canlet.2009.10.017

Cancer Letters
Volume 291, Issue 2 , Pages 230-236 , 28 May 2010

Article Tools

* Image Usage & Resolution